Video

Dr. Goodman on the Importance of the ECHELON-2 Data in PTCL

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

The ECHELON-2 trial was the first multicenter, randomized study that showed a progression-free survival and overall survival (OS) benefit with brentuximab vedotin (Adcetris) plus chemotherapy in patients with newly diagnosed, CD30-expressing PTCL. The population in the study was predominantly patients with anaplastic large cell lymphoma, but it also included some of the more difficult-to-treat PTCLs, including angioimmunoblastic T-cell lymphomas, says Goodman.

The results changed the standard of care for patients with CD30-expressing PTCLs, says Goodman. Now, brentuximab vedotin plus chemotherapy is listed in the guidelines as frontline therapy for patients with PTCL and should be universally adopted as such, concludes Goodman.

Related Videos
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD
Ponatinib in patients with chronic-phase chronic myeloid leukemia and the T315I mutation: 4-year results from OPTIC
John L. Marshall, MD
Petros Grivas, MD, PhD
Noopur S. Raje, MD